This is because of the ability of agonist CD40 to activate antigen presenting cells (APCs), for the priming of antigen specific T cells and its capacity to redirect tumor-infiltrating myeloid cells with anti-tumor and anti-fibrotic activity. Here, CD40 is linked to neoplasm.